ライフサイエンスコーパス: insulin infusion

1 ography) and insulin sensitivity (euglycemic insulin infusion).

2 glycemia ( approximately 100 mg/dl; variable insulin infusions).

3 ucose was clamped at basal levels during the insulin infusion.

4 psies basally and after 30, 45, or 60 min of insulin infusion.

5 ence of severe hyperglycemia unresponsive to insulin infusion.

6 ha had no effect on the SNP response without insulin infusion.

7 nfusion, but not during basal conditions and insulin infusion.

8 Euglycemia was maintained for 24 hours by insulin infusion.

9 c endogenous glucose production (EGP) during insulin infusion.

10 volume was measured at 0, 30, and 90 min of insulin infusion.

11 AAs and EAs after the 20-25 min intravenous insulin infusion.

12 scle were obtained before and after each 3-h insulin infusion.

13 5.5 mmo/l during the night using a variable insulin infusion.

14 (2)H(4)]tyrosine, with and without exogenous insulin infusion.

15 tic subjects during the low but not the high insulin infusion.

16 : the CSF-to-plasma insulin ratio during the insulin infusion.

17 and 50-60% lower (P < 0.05) during the high insulin infusion.

18 ic subjects (P < 0.05) and were unchanged by insulin infusion.

19 muscle and was decreased similarly after 3-h insulin infusion.

20 tion of a high dose continuous peripheral IV insulin infusion.

21 mal levels in the NIDDM group after 4-5 h of insulin infusion.

22 se (100 min, 40 mU x m-2 x min-1) euglycemic insulin infusion.

23 Plasma amino acid concentrations fall during insulin infusion.

24 was evident in response to glucose gavage or insulin infusion.

25 Subcutaneous insulin aspart vs IV regular insulin infusion.

26 use catheters for continuous intraperitoneal insulin infusion.

27 tients do not respond to increasing rates of insulin infusion.

28 n of continuous glucose monitoring (CGM) and insulin infusion.

29 r hour) vs standard-dose (0.1 U/kg per hour) insulin infusion.

30 , and participants with T2D before and after insulin infusion.

31 n was observed in patients given a high-dose insulin infusion.

32 Hypoglycemia was induced and maintained by insulin infusion.

33 cle excitability in vivo from a glucose plus insulin infusion.

34 ral glucose tolerance test and by a low-dose insulin infusion.

35 uppression of HGP by intracerebroventricular insulin infusion.

36 .75 +/- 0.07) and during (0.67 +/- 0.05) the insulin infusion.

37 ose flux was minimal and constant during all insulin infusions.

38 els were lower than in control (portal vein) insulin infusions.

39 dial (-3.1 +/- 0.4 vs. -3.0 +/- 0.6 pmol/kg) insulin infusions.

40 56 +/- 0.14 vs. 0.56 +/- 0.10 mol/l per 6 h) insulin infusions.

41 , and subjects received a 180-min peripheral insulin infusion (0.250 mU kg(-1) x min(-1)) with a vari

42 In stage 1, a 2-h low-dose insulin infusion (0.4 mU.kg-1.min-1) was used to partial

43 The GIR and R(d) rose with increasing insulin infusions (0.8, 2.5, 4, and 20 mU . kg(-1) . min

44 After the control period, plasma insulin infusion 1) was discontinued, creating insulin d

45 min), a basal period (-40 to 0 min), and an insulin infusion (1 mU x kg(-1) x min(-1)) period (0-150

46 we compared the effect of a very low dosage insulin infusion (10 mU x m[-2] x min[-1]) with that of

47 after the basal period, a hyperinsulinemic (insulin infusion = 120 mU x m(-2) min(-1)), hyperglycemi

48 lower mean glucose at the end of 18 hours of insulin infusion (135 +/- 12 mg/dL moderate vs 103 +/- 1

49 n impaired increase in glucose uptake during insulin infusion (169 +/- 28.1% compared with 67 +/- 9.6

50 ncentrations were significantly decreased by insulin infusion (28,450 +/- 9270 vs. 20,830 +/- 8110 mi

51 Three-hour euglycemic-hyperinsulinemic (insulin infusion 30 mU / m / min) clamps were performed

52 ects: NEFA levels (muM) during 8 mU/m(2)/min insulin infusion = 370 +/- 27 vs. 185 +/- 25, P < 0.0001

53 d (P < 0.05 vs. basal) during both AICAR and insulin infusion; [3H]2-deoxy-D-glucose transport activi

54 etes had a higher likelihood of requiring an insulin infusion (44.3% vs 29.3%; p < 0.0001), a higher

55 Peripheral insulin infusion (5 mU/kg per min for 3 h) decreased pla

56 +/-0.09 mmol/l) was induced via jugular vein insulin infusion (50 mU x kg(-1) x min(-1)).

57 +/- 0.1 mmol/l) was induced via jugular vein insulin infusion (50 mU x kg(-1) x min[-1]).

58 ved an insulin bolus (10 units/kg i.v.) plus insulin infusion (50 mU/kg/min i.v.) until hypoglycemia

59 Neither the 40 mU nor the 240 mU insulin infusion affected HK activity.

60 In contrast, insulin infusion after exercise significantly decreased

61 asted state, 0.99 +/- 0.07 (r = 0.74) during insulin infusion and 1.00 +/- 0.05 (r = 0.92) when both

62 n in the nondiabetic subjects during the low insulin infusion and 50-60% lower (P < 0.05) during the

63 ants (81%) receiving continuous subcutaneous insulin infusion and 72 (53%) receiving CGM.

64 We compared standard continuous subcutaneous insulin infusion and closed-loop delivery (n=13; APCam01

65 extent of safety and usability by combining insulin infusion and continuous glucose measurement in a

66 crease in Akt phosphorylation observed after insulin infusion and could theoretically play a role in

67 rd transport of glucose was not increased by insulin infusion and did not differ from values in NIDDM

68 This was accomplished by stopping the portal insulin infusion and giving insulin peripherally at half

69 ng of the test period by stopping the portal insulin infusion and infusing insulin peripherally at tw

70 lamped at approximately 165 mg dl(-1) during insulin infusion and insulin levels reached approximatel

71 Continuous subcutaneous insulin infusion and MDI have similar effects on glycemi

72 investigated the intraportal versus systemic insulin infusion and transendothelial transport of insul

73 relative increase in glucose disposal during insulin infusion) and a 4-fold increase in hepatic insul

74 into a control algorithm calculating rate of insulin infusion, and a nurse adjusted the insulin pump.

75 he first hour, plasma glucose was lowered by insulin infusion, and the second hour constituted a "rec

76 , the use of peritransplantation heparin and insulin infusions, and islet transplant mass remained si

77 GU in NIDDM, but only after several hours of insulin infusion; and 3) The kinetic defect in NIDDM and

78 t a 120-min clamp (2.5-mU . kg(-1) . min(-1) insulin infusion; approximately 120-130 mg/dl glucose) w

79 In group 2, in response to insulin infusion, arterial insulin (pmol/l) was elevated

80 Insulin infusion at 0.4 U kg (-1)min(-1) decreased blood

81 cute fetal hypoglycaemia induced by maternal insulin infusion at 125 dGA.

82 tions and separately during a 6-h euglycemic insulin infusion at 40 mU . m(-2) . min(-1).

83 Insulin infusion at rest did not change the rate of prot

84 oxy-2[18F]fluoro-D-glucose ([18F]FDG) during insulin infusions at three rates (0, 40, and 120 mU/m2 p

85 onditions and during combined amino acid and insulin infusion before and after the supplementation pe

86 Exogenous continuous low-dose insulin infusion, beta blockade with propranolol, and us

87 e I diabetes can be properly controlled with insulin infusion between 0.45 and 0.7muU/mlmin.

88 Plasma leptin remained stable during that insulin infusion, but fell by 37+/-2% in the control exp

89 ly suppressed in the nNOS and WT mice during insulin infusion, but not in the eNOS mice.

90 monitoring (CGM) and continuous subcutaneous insulin infusion can be used to improve the treatment of

91 optical oxygen sensor is integrated into the insulin infusion catheter of an insulin pump.

92 breakdown was significantly decreased during insulin infusion compared with controls (7.98 +/- 1.82 v

93 caused a greater vasodilator response during insulin infusion compared with during sham insulin infus

94 sulin concentration increased 20-fold during insulin infusion compared with saline infusion control (

95 blood glucose measurements and titration of insulin infusion, continuous glucose monitors, and stand

96 ly injections (MDI), continuous subcutaneous insulin infusion (CSII) and islet transplantation to red

97 emic with 4 weeks of continuous subcutaneous insulin infusion (CSII) before randomization to CSII plu

98 Continuous subcutaneous insulin infusion (CSII) is an essential insulin replacem

99 ) with insulin pump (continuous subcutaneous insulin infusion [CSII]), known as artificial pancreas,

100 nsulin pump therapy (continuous subcutaneous insulin infusion; CSII) in patients with type 1 diabetes

101 During Flux 2 (low-dose insulin infusion), D were 89 +/- 3, 98 +/- 6, and 94 +/-

102 During Flux 3 (high-dose insulin infusion): D were 77 +/- 3, 82 +/- 7, and 84 +/-

103 ls between 120 and 180 mg/dL with continuous insulin infusions decreases morbidity in diabetic patien

104 of a chemical sensing unit combined with an insulin infusion device controlled by an algorithm capab

105 he interval before automated glucose-sensing insulin infusion devices become available for the intens

106 Before RSG treatment, insulin infusion did not significantly increase insulin

107 Insulin infusion during low dose hyperinsulinemic-euglyc

108 Preventing the fall in plasma FFAs during insulin infusion either by administering intralipids or

109 Peripheral (leg vein) insulin infusion elevated arterial and hepatic levels 8.

110 With the 0.125 mU/min/kg insulin infusion, FFA fell 40% and HGO fell 33%; prevent

111 With 0.5 mU/min/kg insulin infusion, FFA levels fell 64% while HGO declined

112 kept euglycemic overnight by a variable rate insulin infusion, followed by a 4-h, two-step (insulin 0

113 Seventy patients receiving insulin infusion for >8 hrs were included in data analys

114 2 weeks, whereas a daily repeated acute DVC insulin infusion for 12 days conversely decreased food i

115 s and children regarding a preference for an insulin infusion for the acute management of hyperglycem

116 n update of the guidelines for the use of an insulin infusion for the management of hyperglycemia in

117 ollected immediately after glucose gavage or insulin infusion) from controls showed significant incre

118 Continuous intraperitoneal insulin infusion, from an implanted insulin pump connect

119 Thirty minutes after cessation of insulin infusion, glucose uptake, glycogen synthase acti

120 During both the basal and prandial insulin infusions, glucose disappearance promptly increa

121 In euglycemic clamp studies, insulin infusion greatly increased tyrosine phosphorylat

122 Pharmacologic insulin infusion (group 2) established steady-state huma

123 Saturating insulin infusion (group 3) achieved steady-state human i

124 However, switching off zinc-free insulin infusions had no effect.

125 Hyperinsulinemia induced by insulin infusion, however, did not produce a similar eff

126 od glucose standardization (to 6-7 mmol/L by insulin infusion, if needed) and at 90 min after the mea

127 Conversely, insulin infusion improves coronary flow, even in the set

128 synthesis was not significantly affected by insulin infusion in either normal control subjects or CF

129 obtained by needle biopsy basally and after insulin infusion in four healthy volunteers.

130 Insulin infusion in healthy volunteers elevates serum ur

131 d NO was assessed without insulin and during insulin infusion in the forearm circulation of healthy s

132 Acute insulin infusion in the third cerebral ventricle inhibit

133 se, were suppressed by >50% during AICAR and insulin infusions in both lean and obese rats (P < 0.05

134 the benefits of maintaining euglycemia with insulin infusions in hospitalized patients.

135 ose production higher (P < 0.01) during both insulin infusions in the diabetic compared with the nond

136 als of strict glycemic control achieved with insulin infusions in this patient population are warrant

137 ed that switching off intrapancreatic artery insulin infusions in vivo during hypoglycemia greatly im

138 roprusside infusions, and control continuous insulin infusions-in effect, an artificial pancreas.

139 Unlike leptin, i.c.v. insulin infusion increased basal and baroreflex control

140 Portal vein insulin infusion increased hepatic insulin levels fivefo

141 Insulin infusion increased plasma renin activity (P < 0.

142 Insulin infusion increased protein synthesis at rest (51

143 sal (5.9 +/- 1.1 mmol/l) throughout, whereas insulin infusion increased the arterial insulin level to

144 investigated whether intracerebroventricular insulin infusion increases SNA more in obese male than f

145 ressed in IFG and NFG groups during prandial insulin infusion, indicating that hepatic insulin resist

146 Peripheral IV insulin infusion infiltration should be considered when

147 se monitoring (CGM), continuous subcutaneous insulin infusion (insulin pumps [CSII]), and glucometers

148 When patients were given a low-dose insulin infusion, insulin sensitivity increased by 28.0%

149 Intravenous (IV) insulin infusion is the standard of care for treating di

150 We discovered that the IV insulin infusion line infiltrated, resulting in a large

151 timulate (epinephrine infusion) and inhibit (insulin infusion) lipolysis of adipose tissue TGs.

152 Euglycemic insulin infusion lowered arterial concentrations of free

153 Lipid changes caused by insulin infusion may improve outcomes more than glycemic

154 Insulin infusions may improve outcomes in patients with

155 At baseline and after insulin infusion, MBV and MFV were measured by CEU durin

156 During the insulin infusion, muscle fatty acid oxidation was reduce

157 ere administered either a low or medium dose insulin infusion (n = 10 each group).

158 ial infusions, each group received saline or insulin infusion (n = 6 or 7 each) for an additional 5 h

159 c clamp studies after a 24-h fast, during an insulin infusion of 20 mU x kg(-1) x min(-1).

160 and hepatic glucose output during low-dosage insulin infusion of a hyperinsulinemic clamp (HGO; a mea

161 tic glucose output [HGO] during the low-dose insulin infusion of a hyperinsulinemic clamp) and acute

162 The effects of amino acid supply and insulin infusion on skin protein kinetics (fractional sy

163 (GRADE) methodology to assess the impact of insulin infusions on outcome for general intensive care

164 o blood glucose control to 80-110 mg/dL with insulin infusion or conventional glucose management, whe

165 onventional therapy (continuous subcutaneous insulin infusion or multiple daily insulin injections wi

166 rovascular volume increased within 20 min of insulin infusion (P < 0.01), whereas an effect to increa

167 -60 min (0.68 +/- 0.17 vs. 1.52 +/- 0.26) of insulin infusion (P < 0.05 for both).

168 g insulin infusion compared with during sham insulin infusion (P = 0.02).

169 .001), and this inhibition was larger during insulin infusion (P=0.01) but not further increased by N

170 During insulin infusion, pancreas-transplant patients showed a

171 evels during a 90-min euglycemic intravenous insulin infusion (plasma insulin approximately 700 pmol/

172 Intracoronary insulin infusion produced an approximately 3-fold increa

173 or insulin therapy include use of a reliable insulin infusion protocol, frequent blood glucose monito

174 Intraportal insulin infusions (pulsatile, constant, or reproducing t

175 Continuous insulin infusion pumps have been widely available for ov

176 lunting of the renal vasodilator response to insulin infusion (R(2) = 0.36, P = 0.02) and sensitizing

177 the renal vasodilator response to ARB during insulin infusion (R(2) = 0.59, P < 0.01).

178 Insulin infusion raised plasma insulin concentrations by

179 Intravenous insulin infusion rapidly increases plasma insulin, yet g

180 echnique combined with indirect calorimetry (insulin infusion rate (1.5 mU x kg-1 x min-1)) in 12 mal

181 (24 micromol x kg[-1] x min[-1]) and maximal insulin infusion rate (240 micromol x kg[-1] x min[-1]).

182 The insulin infusion rate (4 mU.kg(-1).min(-1)) was selected

183 (a.m. and p.m., both between 5:00 and 8:00, insulin infusion rate 10 mU/m2/min) (study 2).

184 ved a 7-h euglycemic-hyperinsulinemic clamp (insulin infusion rate = 100 mU x m(-2) x min(-1)), and a

185 At the insulin infusion rate used, the magnitude of this defect

186 At the 0.5 mU x kg(-1) x min(-1) insulin infusion rate, leg FFA release was almost comple

187 reas even with the 1.0 mU x kg(-1) x min(-1) insulin infusion rate, splanchnic FFA release decreased

188 1]) or maximal (240 pmol x kg(-1) x min[-1]) insulin infusion rate.

189 mal (4 mU/kg/min) and maximal (25 mU/kg/min) insulin infusion rates and demonstrated the presence of

190 rotocols were used: 1) euglycemic clamp with insulin infusion rates at 40, 120, 300, and 1,200 mU / m

191 s were randomly assigned and were studied at insulin infusion rates of 0, 20, 40 and 120 mU/min/m2 bo

192 nificantly suppressed glycerol appearance at insulin infusion rates of 10 mU. m(-2). min(-1).

193 The 72-hour average insulin infusion rates were 3.37 +/- 0.61 and 4.57 +/- 1

194 identical glucose levels during the similar insulin infusion rates were substantially lower in diabe

195 The effects of these identical AICAR and insulin infusion rates were then examined in the obese Z

196 (calculated by C-peptide deconvolution) and insulin infusion rates were used as inputs to a new two-

197 In fact, the rates of insulin infusion required to maintain basal hepatic gluc

198 The rates of insulin infusion required to maintain plasma glucose lev

199 2 at baseline to 8 +/- 2 and 10 +/- 3 during insulin infusion, respectively.

200 ogy and device-related challenges, including insulin infusion set failure and sensor signal attenuati

201 phorescence based CGM system into a standard insulin infusion set.

202 e the adhesion of the sensor elements on the insulin infusion set.

203 Whether an insulin infusion should be used for tight control of hyp

204 Insulin infusion significantly increased serum insulin l

205 High-dose insulin infusion stimulated glucose disposal similarly i

206 Low-dose insulin infusion suppressed endogenous glucose productio

207 The essential components of an insulin infusion system include use of a validated insul

208 Implantable insulin infusion systems using the intra-peritoneal rout

209 ptying of hypoglycemia induced by a 5 mU/min insulin infusion (t = 5-90 min) was assessed in consciou

210 yl-L-arginine was significantly higher after insulin infusion than in the absence of hyperinsulinemia

211 insulin by somatostatin, with and without an insulin infusion that elevated insulin to 24.6 +/- 5.2 a

212 ns should be avoided and instead replaced by insulin infusions that normalize and maintain blood gluc

213 howed a dosage-dependent increase during the insulin infusions that was evident within 30-60 min.

214 During fasting conditions (i.e., absence of insulin infusion), the LC for skeletal muscle was slight

215 During the insulin infusion, the mean total peripheral glucose upta

216 rity of the literature supporting the use of insulin infusion therapy for critically ill patients lac

217 Insulin infusion therapy is commonly used in the hospita

218 ements that contribute to safe and effective insulin infusion therapy were determined through literat

219 initive, there are patients who will receive insulin infusion therapy, and the suggestions in this ar

220 were randomly assigned to receive continuous insulin infusion to maintain intraoperative glucose leve

221 Both groups were treated with insulin infusion to maintain normoglycemia after surgery

222 We also showed that chronic insulin infusion to normal C57BL/6J mice resulted in inc

223 Subjects received an overnight insulin infusion to normalize glucose levels, then under

224 Therefore, we hypothesized that insulin infusion to reach normoglycemia, tight glucose c

225 the activation of Akt/PKB, and 3) prolonged insulin infusion under clamp conditions results in a blu

226 n uptake and clearance during an intravenous insulin infusion using compartmental modeling in 10 dogs

227 This study compared insulin infusion via endogenous (hepatic portal vein) an

228 Premeal insulin infusion was also associated with platelet activ

229 ctional phosphorylation of [(18)F]FDG during insulin infusion was also significantly lower in T2D (P

230 6-P concentration in response to the glucose-insulin infusion was approximately 50% less in the IDDM

231 The response to insulin or sham insulin infusion was defined as the change from time 0 t

232 Omental insulin infusion was extracted at approximately 27%, suc

233 Leg glucose uptake in response to the 40-mU insulin infusion was higher in the lean control subjects

234 In group 3 (n = 4), the human insulin infusion was increased to a saturating dose (120

235 In a control group (n=5), the portal insulin infusion was not changed and glucose was infused

236 No response was observed when the SPDa insulin infusion was not turned off (peak change within

237 rom 60 to 150 min of exercise, the simulated insulin infusion was sustained (C; n = 7), modified to s

238 After a basal sampling period, insulin infusion was switched from the portal vein to a

239 SPDa insulin infusion was switched off simultaneously when bl

240 Glucose infusion rate in response to insulin infusion was used to define insulin resistance (

241 y (percent increase in glucose uptake during insulin infusion) was greatest in the Lean group (576% +

242 ed insulin pumps for continuous subcutaneous insulin infusion were randomly assigned to 2 months of A

243 ion rates during both low-dose and high-dose insulin infusions were lower in pancreas-transplant pati

244 This was confirmed during preprandial insulin infusion when glucose disposal was lower (P < 0.

245 After the low-dose insulin infusion, which achieved postabsorptive insulin

246 ximately 700 pmol/l by means of an exogenous insulin infusion, while EGP, SGU, and leg glucose uptake

247 s were maintained constant with an exogenous insulin infusion, while endogenous hormone secretion was

248 During high-dose insulin infusion, whole-body glucose disposal was low an

249 After 2 h of insulin infusion, whole-body glucose infusion rate was s

250 s/kg/min) and maximal (20 milliunits/kg/min) insulin infusions, whole-body glucose disposal was 77% (

251 ff), and forearm glucose uptake (FGU) during insulin infusion with 60 min of euglycemia followed by 6

252 e MiniMed 640G pump (continuous subcutaneous insulin infusion) with self-monitoring of blood glucose

253 compared with use of continuous subcutaneous insulin infusion without real-time CGM.